Nov 30, 2021 | by Kelly Prymicz, Commentary, Specialty Drug Management
If you’re a plan sponsor, you’re probably familiar with the drug Humira. That’s undoubtedly because it appears toward the top of your list of costliest drugs. Well, that might change soon. Or maybe not. It’s tough to tell. (more…)
Nov 29, 2021 | Commentary, Specialty Drug Management
What keeps you awake at night? For a couple years now, we’ve written about the number of mega-expensive new cell and gene therapies in the development pipeline. By “mega,” we generally mean therapies costing more than a million dollars. (more…)
May 28, 2021 | Commentary, Specialty Drug Management
Chelko uses our unique clinical and sourcing expertise to dramatically reduce drug benefit costs for plan sponsors and improve member care. While others mistakenly chase discounts and rebates, we focus on removing waste and excessive profiteering from plans and helping members more affordably get the medications they need.
The fact is, too many people are using old strategies to take on new challenges. While brand and generic medications make up almost 99% of total prescriptions and have long been the primary focus of most cost reduction efforts, it’s more than time to shift our attention to the other 1%. (more…)
Mar 29, 2021 | by Lucia Vescera, Commentary, Specialty Drug Management
The world is full of patients suffering from diseases without available therapeutic options and the FDA’s “accelerated approval” pathway offers many an additional degree of hope. Introduced in 1992 and later modified in 2012, the program is not without its downsides. (more…)
Jan 12, 2021 | News, Specialty Drug Management
On behalf of everyone at Chelko and our clients, we would like to recognize the efforts of Lucia Vescera and Kelly Prymicz on National Pharmacist Day. (more…)
Oct 29, 2020 | Commentary, Specialty Drug Management
Anyone who’s followed our firm lately has probably heard us talk about the $1 million+ drugs already here and those coming to market over the next few years. While early in the game, we’ve already had a few clients incur enormous claims for these budget-busting medications.
It’s likely many of you reading this are familiar with some of the well-known drugs out there, but according to our latest survey, 73% of employers do not have a plan in place to avoid surprises related to high cost therapies like the ones we’re discussing. And while some of you may have a stop loss policy in place as a safety net to protect against such catastrophic claims, unfortunately, that may not be a foolproof strategy. (more…)